Aclaris therapeutics appoints robert doody as vice president, investor relations

Wayne, pa., sept. 27, 2022 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has appointed robert a. doody jr. as vice president, investor relations.
ACRS Ratings Summary
ACRS Quant Ranking